MX2021015499A - Derivados de 2h-indazol y su uso en el tratamiento de enfermedades. - Google Patents
Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.Info
- Publication number
- MX2021015499A MX2021015499A MX2021015499A MX2021015499A MX2021015499A MX 2021015499 A MX2021015499 A MX 2021015499A MX 2021015499 A MX2021015499 A MX 2021015499A MX 2021015499 A MX2021015499 A MX 2021015499A MX 2021015499 A MX2021015499 A MX 2021015499A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- indazole derivatives
- further provides
- invention further
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención hace referencia a derivados de 2H-indazol de fórmula (I'); o una sal farmacéuticamente aceptable de este,(Ver Fórmula I'); en los cuales todas las variables son tal como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4; además, la invención proporciona un método para fabricar compuestos de la invención y métodos para su uso terapéutico; la invención también proporciona métodos para su preparación, para su uso médico, en particular, para su uso en el tratamiento y el control de enfermedades o trastornos que incluyen una enfermedad inflamatoria, una enfermedad autoinmunitaria, cáncer, una enfermedad cardiovascular, una enfermedad del sistema nervioso central, una enfermedad de la piel, una afección y enfermedad oftálmica, y una enfermedad ósea.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867521P | 2019-06-27 | 2019-06-27 | |
PCT/US2020/039346 WO2020263967A1 (en) | 2019-06-27 | 2020-06-24 | 2h-indazole derivatives and their use in the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015499A true MX2021015499A (es) | 2022-04-20 |
Family
ID=71608086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015499A MX2021015499A (es) | 2019-06-27 | 2020-06-24 | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230002361A1 (es) |
EP (1) | EP3990432A1 (es) |
JP (1) | JP2022539374A (es) |
KR (1) | KR20220042132A (es) |
CN (1) | CN114585609A (es) |
AR (1) | AR119244A1 (es) |
AU (1) | AU2020304036A1 (es) |
BR (1) | BR112021026369A2 (es) |
CA (1) | CA3145043A1 (es) |
CL (1) | CL2021003458A1 (es) |
CO (1) | CO2022000657A2 (es) |
CR (1) | CR20220036A (es) |
IL (1) | IL289167A (es) |
JO (1) | JOP20210324A1 (es) |
MA (1) | MA56392A (es) |
MX (1) | MX2021015499A (es) |
PE (1) | PE20220517A1 (es) |
TW (1) | TW202116735A (es) |
UY (1) | UY38765A (es) |
WO (1) | WO2020263967A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
AU2021409546A1 (en) * | 2020-12-22 | 2023-07-06 | Biogen Ma Inc. | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease |
IL303931A (en) * | 2020-12-22 | 2023-08-01 | Biogen Ma Inc | History of 2H-indazole as IRAK4 inhibitors and their use to treat diseases |
UY39844A (es) * | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
CN113651810B (zh) * | 2021-07-16 | 2023-10-13 | 上海毕得医药科技股份有限公司 | 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法 |
KR20240051921A (ko) | 2022-02-14 | 2024-04-22 | 아스트라제네카 아베 | Irak4 억제제 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
CA2647545C (en) * | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
JP2010502717A (ja) * | 2006-09-07 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターロイキン1受容体関連キナーゼの調節物質 |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
US10029988B2 (en) * | 2013-03-15 | 2018-07-24 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
ES2703851T3 (es) * | 2014-08-22 | 2019-03-12 | Merck Patent Gmbh | Indazoles |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
EA201890307A1 (ru) * | 2015-07-15 | 2018-10-31 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные и азаиндазольные соединения как ингибиторы irak-4 |
CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
CN105559944B (zh) * | 2015-12-14 | 2016-11-09 | 李雷 | 覆膜血管支架 |
CN109153665B (zh) * | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
-
2020
- 2020-06-24 UY UY0001038765A patent/UY38765A/es unknown
- 2020-06-24 PE PE2021002236A patent/PE20220517A1/es unknown
- 2020-06-24 AU AU2020304036A patent/AU2020304036A1/en not_active Abandoned
- 2020-06-24 US US17/623,182 patent/US20230002361A1/en active Pending
- 2020-06-24 MX MX2021015499A patent/MX2021015499A/es unknown
- 2020-06-24 AR ARP200101792A patent/AR119244A1/es unknown
- 2020-06-24 CR CR20220036A patent/CR20220036A/es unknown
- 2020-06-24 KR KR1020227003147A patent/KR20220042132A/ko unknown
- 2020-06-24 MA MA056392A patent/MA56392A/fr unknown
- 2020-06-24 JP JP2021577477A patent/JP2022539374A/ja active Pending
- 2020-06-24 EP EP20740146.4A patent/EP3990432A1/en active Pending
- 2020-06-24 JO JOP/2021/0324A patent/JOP20210324A1/ar unknown
- 2020-06-24 CN CN202080053737.3A patent/CN114585609A/zh active Pending
- 2020-06-24 CA CA3145043A patent/CA3145043A1/en active Pending
- 2020-06-24 BR BR112021026369A patent/BR112021026369A2/pt not_active Application Discontinuation
- 2020-06-24 WO PCT/US2020/039346 patent/WO2020263967A1/en active Application Filing
- 2020-06-24 TW TW109121728A patent/TW202116735A/zh unknown
-
2021
- 2021-12-20 IL IL289167A patent/IL289167A/en unknown
- 2021-12-23 CL CL2021003458A patent/CL2021003458A1/es unknown
-
2022
- 2022-01-25 CO CONC2022/0000657A patent/CO2022000657A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020263967A1 (en) | 2020-12-30 |
PE20220517A1 (es) | 2022-04-07 |
KR20220042132A (ko) | 2022-04-04 |
BR112021026369A2 (pt) | 2022-05-17 |
CL2021003458A1 (es) | 2022-08-19 |
CR20220036A (es) | 2022-05-04 |
CO2022000657A2 (es) | 2022-04-29 |
US20230002361A1 (en) | 2023-01-05 |
JOP20210324A1 (ar) | 2023-01-30 |
AU2020304036A1 (en) | 2022-01-06 |
JP2022539374A (ja) | 2022-09-08 |
IL289167A (en) | 2022-02-01 |
EP3990432A1 (en) | 2022-05-04 |
CN114585609A (zh) | 2022-06-03 |
WO2020263967A8 (en) | 2021-01-28 |
AR119244A1 (es) | 2021-12-01 |
MA56392A (fr) | 2022-05-04 |
CA3145043A1 (en) | 2020-12-30 |
UY38765A (es) | 2021-01-29 |
TW202116735A (zh) | 2021-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220036A (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
JOP20210322A1 (ar) | مشتقات من إيميدازو[1 ،2-a] بيريدينيل واستخدامها في علاج مرض | |
MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
NZ739211A (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
MX2018006370A (es) | Inhibidores de proteina quinasa, metodo de preparacion y su uso medico. | |
WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
CY1110770T1 (el) | Χρηση των (r)-(αλογονοβενζυλοξυ) βενζυλαμινο-προπαναμιδιων ως επιλεκτικων διαμορφωτων διαυλου νατριου και/ή ασβεστιου | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
CO2023009316A2 (es) | Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades | |
MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
JOP20220102A1 (ar) | مثبطات المُسْتقبلة الأدرينِية adrac2 | |
Jiang et al. | Lithium affects rat hippocampal electrophysiology and epileptic seizures in a dose dependent manner | |
CR20230318A (es) | Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades | |
WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
CN111511373A (zh) | 神经系统疾病治疗剂 | |
CN109966278B (zh) | 草酰苹果酸在制备治疗神经细胞损伤的药物中的应用 | |
MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
US8182844B2 (en) | Use of Clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
Steinbach et al. | High-Frequency Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Neuropathic Pain After a II–III Degree Burn | |
EP4327869A3 (en) | Methods of treating fabry patients having renal impairment | |
Millichap et al. | Controlled evaluation of primidone and diphenylhydantoin sodium: comparative anticonvulsant efficacy and toxicity in children | |
MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
CN107648235B (zh) | 普纳替尼在制备治疗缺血/再灌注损伤药物中的应用 | |
Wu | Toxic epidermal necrolysis: case report |